While reinforcing the importance of treating all known risk factors that contribute to atherosclerotic cardiovascular disease, ASCVD, physicians also need to recognize and treat systemic inflammation in CV disease, according to Dr. Quigley, who addresses the importance of identifying and reducing residual inflammatory risk.
1. Colchicine did not significantly reduce the risk of atrial fibrillation or myocardial injury after non-cardiac surgery. 2. Use of colchicine was associated with a higher incidence of non-infectious diarrhea. Evidence Rating Level: 1 (Excellent) Study Rundown: Colchicine is an anti-inflammatory drug that may be used for the management of gout and pericarditis. Patients with
Colchicine, a widely available gout medication, has been approved by the FDA to be used in low doses to prevent cardiovascular events in patients with coronary disease.
Low dose colchicine gets FDA approval for secondary prevention of heart disease medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
The FDA has approved Lodoco (colchicine) to reduce the risk of cardiac events in patients with established atherosclerotic disease or multiple risk factors for CV disease.